RecruitingPhase 2NCT06989099

Lymphedema Prevention Through Immediate Lymphatic Reconstruction (LILY) Trial.

Lymphedema Prevention Through Immediate Lymphatic Reconstruction (LILY) Trial


Sponsor

M.D. Anderson Cancer Center

Enrollment

50 participants

Start Date

Sep 24, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

To learn if reconstruction of the lymphatic system at the time of axillary lymphadenectomy can reduce the risk of developing lymphedema.


Eligibility

Min Age: 18 Years

Inclusion Criteria5

  • Participants diagnosed with IBC.
  • Participants who have been scheduled for ILR/pLVB by their treating physician/surgeon at the time of their axillary lymphadenectomy for breast cancer
  • Participants willing and able to comply with the study protocol requirements and all study-related visit requirements.
  • Female subjects at least 18 years old and capable of providing consent to participate.
  • Females of childbearing potential must have a negative urine pregnancy test within 36 hours prior to study drug administration and agree to use a medically accepted method of contraception for a period of one month following the study.

Exclusion Criteria8

  • Patients known to be pregnant or breast-feeding.
  • Patients with known or suspected iodine or ICG hypersensitivity.
  • Patients unable to remain stationary for one hour.
  • Active cellulitis.
  • Subjects with a preoperative clinical lymphedema diagnosis.
  • Subjects undergoing bilateral ALND.
  • Subjects requiring immediate chest wall reconstruction with a pedicled or microvascular flap, or those that have received preoperative radiation therapy.
  • Patients with BMI >45kg/m2.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREImmediate Lymphatic Reconstruction (ILR)/

Given by Procedure

PROCEDUREProphylactic Lymphovenous Bypass (pLVB)

Given by Procedure


Locations(1)

MD Anderson Cancer Center

Houston, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06989099


Related Trials